Accepted for/Published in: Journal of Medical Internet Research
Date Submitted: Sep 29, 2024
Open Peer Review Period: Oct 2, 2024 - Nov 27, 2024
Date Accepted: Jan 9, 2025
(closed for review but you can still tweet)
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Effectiveness of continuous glucose monitoring on short-term in-hospital mortality among frail critically ill patients with COVID-19
ABSTRACT
Background:
Objective We aimed to investigate the effectiveness of CGM on intensive care unit (ICU) related outcomes among frail and critically ill patients with confirmed COVID-19. Research design and methods This was an exploratory, prospective, randomized, open-label, parallel, single-center clinical trial. A total of 124 patients was finally analyzed. The primary outcome was 28-day in-ICU mortality. The secondary outcome included the length of ICU stay, the occurrence of hypoglycemia and severe hypoglycemia events. Results The mean age was 78.3±11.5 years old. The mean fasting glucose level at baseline was 8.12±1.54 mmol/L. The mean HbA1c level was 7.2±0.8%. The percentage of participants with diabetes was 30.6%. The corresponding hazard ratio of the primary outcome in the isCGM group when compared with the POCT group was 0.18 (95%CI 0.04-0.79). The average length of ICU stay was 10.0±7.57 days in the isCGM group and 14.0±6.86 days in the POCT group (P < 0.05). Conclusions We found a significant clinical benefit from the use of CGM among frail and critically ill patients with COVID-19. These findings support the use of CGM in ICU and might help with the extension of application in various in-hospital settings.
Objective:
We aimed to investigate the effectiveness of CGM on intensive care unit (ICU) related outcomes among frail and critically ill patients with confirmed COVID-19.
Methods:
This was an exploratory, prospective, randomized, open-label, parallel, single-center clinical trial. A total of 124 patients was finally analyzed. The primary outcome was 28-day in-ICU mortality. The secondary outcome included the length of ICU stay, the occurrence of hypoglycemia and severe hypoglycemia events.
Results:
The mean age was 78.3±11.5 years old. The mean fasting glucose level at baseline was 8.12±1.54 mmol/L. The mean HbA1c level was 7.2±0.8%. The percentage of participants with diabetes was 30.6%. The corresponding hazard ratio of the primary outcome in the isCGM group when compared with the POCT group was 0.18 (95%CI 0.04-0.79). The average length of ICU stay was 10.0±7.57 days in the isCGM group and 14.0±6.86 days in the POCT group (P < 0.05).
Conclusions:
We found a significant clinical benefit from the use of CGM among frail and critically ill patients with COVID-19. These findings support the use of CGM in ICU and might help with the extension of application in various in-hospital settings.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.